Contrast Sonography for Evaluation of Liver Tumors Prior to Radiofrequency Ablation

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the efficacy of the Definity (perflutren lipid microsphere Injectable Suspension) ultrasound contrast agent in identifying small tumors (hepatomas & metastases) within the liver.

Primary objective: To estimate the increase in conspicuity of small intrahepatic tumors with contrast-enhanced sonography

Secondary Objectives: To estimate the effect of tumor type, size, location and depth on the conspicuity of small tumors on contrast-enhanced sonography

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, Davis

Criteria

Inclusion Criteria:

• Patients with primary hepatocellular carcinoma (HCC) or secondary (metastatic) carcinoma of the liver who have been referred for ultrasound-guided radiofrequency ablation (RFA) treatment

• Recent (within 90 days) CT or MRI scan with report of one or more tumors ≤ 1.5 cm in diameter

• Patient is stable and is to be managed conservatively (i.e. non-surgically)

• 18 years of age or older

• Ability and willingness to provide written informed consent

Exclusion Criteria:

• Known or suspected cardiac shunt(s)

• Known sensitivity to octafluoropropane

• Pregnant or breastfeeding